摘要
Elabela是一种新发现的小分子肽类激素,是G蛋白偶联受体-血管紧张素1型受体同源序列受体蛋白Apelin-血管紧张素样受体(apelin-angiotensin receptor-like,APJ)的新型内源性配体。Elabela主要在成人肾脏、多能干细胞、血管内皮细胞中表达,并与其受体APJ结合发挥一系列生物学效应,包括促进血管生成、降低血压、调节体液稳态及心血管功能等。近年来越来越多的研究发现Elabela在肾脏疾病的发生发展中发挥重要的保护作用,因此本文就Elabela在急、慢性肾脏疾病(肾缺血/再灌注损伤、脓毒症相关肾损伤、高血压肾病、糖尿病肾脏疾病和肾癌)中的研究进展做一综述,以期为临床上治疗肾脏疾病提供新的途径和方法。
Elabela is a new endogenous peptidic ligand for G protein-coupled receptor-APJ with a strong sequence homology with angiotensin type 1 receptor(AT1).Conjugating with its receptor Apelin-angiotensin receptor-like(APJ)to exert a series of biological effects,Elabela is predominantly expressed in adult kidneys,pluripotent stem cells and vascular endothelial cells.It plays an important role in promoting angiogenesis,lowering blood pressure and regulating fluid homeostasis and cardiovascular system.Recent studies have demonstrated that Elabela is involved in the progression of kidney disease.Therefore this review provided an updating of current researches on the role of Elabela in acute and chronic kidney diseases including renal ischemia/reperfusion injury,sepsis-related kidney injury,hypertensive nephropathy,diabetic nephropathy and kidney cancer.It may offer a new therapeutic approach of kidney diseases.
作者
王子葳
石敏
陈娟
张红
Wang Zi-wei;Shi Min;Chen Juan;Zhang Hong(Department of Endocrinology,Affiliated First Municipal People’s Hospital,Nanjing Medical University,Huai’an 223300,China)
出处
《临床肾脏病杂志》
2021年第10期866-870,共5页
Journal Of Clinical Nephrology
基金
国家自然科学基金(81700723、82000743)
江苏省自然科学基金(BK20191213)。
